TNF Blockers News and Research

RSS
JAK inhibitors and tocilizumab elicit better response rates in VEXAS syndrome

JAK inhibitors and tocilizumab elicit better response rates in VEXAS syndrome

People with inflammatory immune conditions had increased risk of COVID-19-related death before vaccination

People with inflammatory immune conditions had increased risk of COVID-19-related death before vaccination

Researchers say that NSAIDs, JAK inhibitors and TNF blockers are safe to use in COVID-19

Researchers say that NSAIDs, JAK inhibitors and TNF blockers are safe to use in COVID-19

New study helps identify drugs that are safe for treating COVID-19

New study helps identify drugs that are safe for treating COVID-19

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

FDA approves treatment for adults with non-radiographic axial spondyloarthritis

Genetic test to predict IBD severity in children

Genetic test to predict IBD severity in children

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Bonn scientists identify immune factor partially responsible for chronic viral infection

Bonn scientists identify immune factor partially responsible for chronic viral infection

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

AbbVie’s Phase 3 pivotal study shows HUMIRA is effective in reducing symptoms in HS

Clinical studies to treat unmet medical need post-transplantation

Clinical studies to treat unmet medical need post-transplantation

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

Scientists discover how lymphotoxin controls production of immunoglobulins in gut

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.